Page 19 - Stroke Statistics News Today

Amarin Highlights Multiple VASCEPA® (Icosapent Ethyl)-Related Scientific Findings Presented at National Lipid Association (NLA) Scientific Sessions 2020, Including First COVID-19 Clinical Results December 14, 2020 05:00 ET | Source: Amarin Corporation plc Amarin Corporation plc Bedminster, New Jersey, UNITED STATES REDUCE-IT® EPA Encore Presentation reinforces Eicosapentaenoic Acid (EPA) levels from VASCEPA® (icosapent ethyl) strongly correlated to...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Reports Encouraging Efficacy and Safety Results from Pilot Study Treating COVID-19 ... Amarin Corporation plcDecember 13, 2020 GMT VASCEPA COVID-19 CardioLink-9 Randomized Trial suggests improvement in patient-reported COVID-19 symptoms while achieving its primary endpoint by demonstrating a 25% reduction in high-sensitivity C-reactive protein (hsCRP) with encouraging short-term safety and tole...